Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study

OBJECTIVE: The therapeutic effect of pemafibrate on metabolic dysfunction-associated fatty liver disease (MAFLD) remains unknown. This retrospective, single-arm study investigated the efficacy and safety of pemafibrate in MAFLD patients with hypertriglyceridemia. METHODS: A total of 10 patients who...

Descripción completa

Detalles Bibliográficos
Autores principales: Hatanaka, Takeshi, Kakizaki, Satoru, Saito, Naoto, Nakano, Yuya, Nakano, Sachi, Hazama, Yoichi, Yoshida, Sachiko, Hachisu, Yoko, Tanaka, Yoshiki, Kashiwabara, Kenji, Yoshinaga, Teruo, Tojima, Hiroki, Naganuma, Atsushi, Uraoka, Toshio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8355409/
https://www.ncbi.nlm.nih.gov/pubmed/33612679
http://dx.doi.org/10.2169/internalmedicine.6574-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8355409/
https://www.ncbi.nlm.nih.gov/pubmed/33612679
http://dx.doi.org/10.2169/internalmedicine.6574-20

Ejemplares similares